Clinical Trial Update: Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating crizotinib in patients with ALK, MET, or ROS1 alterations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Cancer
• Solid Tumor

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: UNICANCER | Conditions: Hematologic Cancers, Solid Tumors | Phase 2 | Status: COMPLETED